Genome editing has advanced at a rapid pace with promising results for treating genetic conditions—but there is always room ...

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions-but there is always room for improvement.

Researchers have developed a machine learning model that predicts Cas9 proteins that can be tailored with designer properties for therapeutic use.

Latest study leverages new constructs for nuclear localization signal (NLS) sequences to improve editing efficiency in human ...

The agreement grants Jumpcode access to ERS' CRISPR/Cas9 patent portfolio, empowering the company to advance the sensitivity and efficiency of next-generation sequencing (NGS) and expand ...

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ®Seeks to expand licensing of its proprietary CRISPR RNP technologySEOUL, South Korea, April 21, 2025 /PRNewswi ...

In a new development, researchers have successfully created an efficient two-line system for hybrid seed production in ...

Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia ...

In a shining moment for Uganda and the African scientific community, Dr Matthias Magoola, founder of Dei Biopharma, has been ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to develop ...